Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

The Effects of Aprotinin on ACT and the Total Amount of Heparin for Open Heart Surgery

개심술에서 Aprotinin이 heparin 사용량 및 ACT에 미치는 영향

  • 이현우 (가천의과대학교 부속 길병원 심장센터 흉부외과) ;
  • 이재웅 (가천의과대학교 부속 길병원 심장센터 흉부외과) ;
  • 박철현 (가천의과대학교 부속 길병원 심장센터 흉부외과) ;
  • 박국양 (가천의과대학교 부속 길병원 심장센터 흉부외과)
  • Published : 2000.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background; Aprotinin, which is a nonspecific serine protease inhibitor, has an antiinflammatory and thrombogenic effect. However, it has an antithrombogenic effect during the cardiopulmonary bypass. This study was performed to evaluated the effects of aprotinin on the activated clotting time(ACT) and the total amount of the heparin used during the cardiopulmonary bypass. Marterial and Method; From December 1998 to November 1999, 82 consecutive patients electively underwent open heart surgery at Gachon medical school. The patients were older than 18 years. Eighty two patients were classified into a control group(group C, n=36) and a aprotinin-treated group(group A, n=46). Body weight, height, body surface area(BSA), pump time(PT), aortic cross clamping time(ACCT), and body temperature(BT) were determined. Total amount of heparin and protamine during the CPB were also measured. ACT was determined before heparin administration, at 20, 40 and 60 minutes after heparin administration, and after protamine administration. Result; No significant differences were noted in either group in body weight, height, BSA, BT, and the total amoun of heparin and protamine. Group A demonstrated a significant(p <0.05) increase in age, PT, ACCT, and ACT at 20, 40, and 60 minutes after heparin administration. Conclusion; In summary, the use of aprotinin prime resulted in an increase in ACT. The total amount of heparin in aproinin-treated patient was similar to that of the control group in spite of having the prolonged pump time. Therefore aprotinin may reduce the requirement of heparin.

배경; 아프로티닌(Aprotinin)은 nonspecific serine protease inhibitor로 개심술에서 항염효과와 혈액 응고효과를 갖고 있다. 또한 아프로티닌은 심폐기 작동 중에는 항트롬빈(antithrombin) 효과가 있다. 본 연구는 아프로티닌이 헤파린(heparin)사용 양 및 ACT(activated clotting time) 에 어떠한 영향을 미치는 가를 알아보기 위하여 시행하였다. 대상 및 방법; 1998년 12월 1일부터 1999년 11월 30일 까지 본원에서 개심술을 받은 환자 중 연령이 18세 이상인 82명을 대상으로 연구하였다. 환자들은 아프로티닌을 사용한 군(Group A)과 사용하지 안흥ㄴ 군(Group C)으로 나누어 연구하였다. 모든 환자에서 수술 전 체중, 신장, 체표면적, pump time, ACC time 등을 조사하였다. ACT의 측정 시기는 헤파린 공급 전, 공급 후 20분, 40분, 60qs과 프로타민 공급 후 20분 등이었다. 또한 ACT 변화 정도를 알아보기 위하여 헤파린 공급 전과 공급 후 20분, 공급 후 40분과 20분 사이의 차이를 조사하였다. 결과; 연구 대상 환자들이 굴변 특징에서는 연령, 펌프시간 및 대동맥차단 사간에서 모두 A군에서 증가된 소견을 보였다. (p<0.05). 헤파린 공급 전과 프로타민 공급 후의 ACT는 두 군에서 차이가 없으며 헤파린 공급 후 20분(607$\pm$22.3, 525$\pm$169초), 40분(889$\pm$315, 546$\pm$103초), 60분 (748$\pm$310, 472$\pm$115 초)에 측정한 ACT는 모두 A군에서 증가된 소견을 보였다. (p<0.05), 헤파린 공급 전과 궁급 후 20분 사이의 ACT 차이는 A한 군에서 증가된 소견을 보였고(p<0.05), 헤파린 공급 후 40분과 20분 사이의 ACT의 차이 또한 A군에서 증가된 소견을 보였다. (p<0.05). 두 군간의 총 헤파린 및 프로타민 사용 양에는 차이가 없었다. (p>0.05). 결론; 결론적으로 아프로티닌은 본 연구에서 CPB time을 고려해 볼 때 헤파린사용 양을 의미있게 줄여 줄 수 있을 것으로 생각되며 또한 ACT를 증가시켜 주기 때문에 추가적인 헤파린 감량이 가능할 것으로 생각된다.

Keywords

References

  1. Ann Thorac Surg v.60 Heparin causes platelet dysfunction and influence fibrinolysis before cardipulmonary bypass Khuri SF;Valeri R;Loscalzo J(et al.)
  2. Ann Thorac Surg v.67 A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperation McCarhy PM;Yared JPP;Foster RC(et al.)
  3. Ann Thorac surg v.60 High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes Ovrun E;Mollnes TE;Fosse E(et al.)
  4. Ann Thorac Surg v.60 Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects Ovrum E;Holen EA;Tangen G(et al.)
  5. Ann Thorac Surg v.62 Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study Aldea GS;Doursounian M;O'Gara P;Treanor P(et al.)
  6. Ann Thorac Surg v.26 Adequate anticoagulation during cardipulmonary bypass determined by activated clotting time and appearance of fibrin monomer Yong JA;Kisher CT;Doty DB
  7. J Thorac Cardiovasc Surg v.101 A reevaluation of heparin requirements for cardiopulmonary bypass Cardoso PFG;Yamazaki F;Keshavjee S(et al.)
  8. Ann Thorac Surg v.58 Risk and benefits of low systemic heparinization during open heart operation Von Segesser LK;Weiss BK;Pasic M(et al.)
  9. Ann Thorac Surg v.67 Reduced inotropic support after aprotinin therapy during pediatric cardiac operations Wippermann CF;Schmid FX;Eberle B(et al.)
  10. Ann Thorac Surg v.67 Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation Alonso A;Whitten CW;Hill GE
  11. Ann Thorac Surg v.65 Aprotinin enhances the endogenous release of interneukin-10 after cardiac operation Hill GE;Diego RP;Stammers AH(et al.)
  12. Ann Thorac Surg v.68 Cardiac transplantation in a patient with protein C deficiency Spanier TB;Chen JM;Mancini DM(et al.)
  13. J Cardiothorac Vasc Anesth v.13 no.4 Suppl Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update Despotis GJ;Joist JH
  14. J Cardiovasc Pharmacol v.27 no.Suppl 1 Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin Dietrich W
  15. Ann Thorac Surg v.55 no.4 Aprotinin in perspective Westaby S
  16. Ansethesiology v.83 no.4 Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study Dietrich W;Dilthey G;Spannagl M(et al.)
  17. Ann Thorac Surg v.62 Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance Ovrum E;Holen EA;Tangen G;Rindar MAL
  18. Ann Thorac Surg v.60 Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass Khuri SF;Valeari CR;Loscalzo J(et al.)
  19. Ann Thorac Surg v.59 Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements Despotis GJ;Joist H;Joiner Maier D(et al.)
  20. Ann Thorac Surg v.66 Activation of the protein C system during cardiopulmonary bypass with and without aprotinin Speekenbrink RGH;Bertina RM;Espana F(et al.)